L.E.A.F. Pharmaceuticals LLC, a global pharmaceutical company, announced Wednesday it is setting foot in Rwanda.

L.E.A.F. Rwanda Ltd, a biotechnology company will be headquartered in Kigali.

The parent firm is located in the historic area of Valley Forge, Pennsylvania, USA, with a mission to discover, develop and commercialise innovative and safe therapies for cancer.

The company expects to focus on establishing Rwanda as a hub for biotechnology Research and Development (R&D) as well as pharmaceutical manufacturing in Africa.

The Kigali company will work to attract and retain highly skilled biotechnology scientists and clinical researchers from Africa and beyond, in a quest to discover and develop innovative medicines against diseases that predominantly afflict the health of the African population, according to a statement.

L.E.A.F. Rwanda will partner with L.E.A.F. Pharmaceuticals to facilitate advanced skills transfer to the continent, for long term sustainability of a robust biotechnology industry in Africa.

"Historically, innovative lifesaving medicines have taken too long to reach the African population, if at all. A key component of L.E.A.F. Rwanda's mission is to focus on expeditiously making available such medicines to the African population," Founder, President, and CEO of L.E.A.F. Pharmaceuticals, Dr. Clet Niyikiza said in the statement.

Since pharmaceuticals company began operations in August 2014, the it has filed nearly a dozen patent applications to protect its intellectual property.

The new company in partnership with L.E.A.F. Pharmaceuticals, anticipates making available its first anticancer medicine in Africa starting in 2019.

L.E.A.F. Pharmaceuticals also harnesses scientific advances and breakthroughs in molecular biology and biochemistry, and re-engineers failed or non-effective yet promising molecules, with the goal to discover new, safer and more effective medicines.

editorial@newtimes.co.rw